%D9%85%D9%8A%D8%B1%D8%A7%D8%A8%D9%8A%D8%BA%D8%B1%D9%88%D9%86Category:MirabegronMirabegronMirabegronMirabegroniMirabegron%E3%83%9F%E3%83%A9%E3%83%99%E3%82%B0%E3%83%AD%E3%83%B3Mirabegron%E0%AC%AE%E0%AC%BF%E0%AC%B0%E0%AC%BE%E0%AC%AC%E0%AD%87%E0%AC%97%E0%AD%8D%E0%AC%B0%E0%AC%A8%E1%B1%A2%E1%B1%A4%E1%B1%A8%E1%B1%9F%E1%B1%B5%E1%B1%AE%E1%B1%9C%E1%B1%A8%E1%B1%9A%E1%B1%B1MirabegronMirabegronQ3702534
about
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy SubjectsTreatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. MirabegronTreatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia OceaniaMirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized StudyThis Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive BladderPost-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of TolterodineEffectiveness of a Structured Intervention to Optimize the Use of MirabegronTo Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken TogetherA Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet FormulationTo Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly FemalesTo Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of MetoprololA Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult VolunteersA Study to Evaluate Cardiovascular Interactions Between Mirabegron and TamsulosinA Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive BladderA Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy VolunteersA Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin SimultaneouslyA Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive PillComparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURPA Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and ChinaMirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot StudyBeta 3 Agonist Treatment in Heart Failure-2Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor OveractivityImpact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder SyndromeMirabegron And Ureteral Stent-related Pain (MAP) TrialEfficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
P4844
Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study.Mirabegron for the treatment of overactive bladder.Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.Mirabegron: a safety review.Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.β-adrenoceptor agonist effects in experimental models of bladder dysfunction.Use of mirabegron in treating overactive bladder.Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord InjuryInvestigation of the reasons for withdrawal from long-term treatment with mirabegron of treatment-naïve Japanese female patients with overactive bladder in the real-world clinical settingThree-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance studyAn aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxantIdentification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist[Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder]Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction
P921
Q61862249-9992A6A9-6383-41A4-86B2-3ECCD9E62CC7Q61894665-0AB2E0C6-332F-481A-9682-38389F6EF36FQ61905157-DC2505EF-AD17-45D5-96F4-A0377134FDF8Q61907549-2219AD7C-7C9B-4FB0-8DFB-C55C3722D91DQ61907684-6A0A1D75-64FE-4FB7-9A3D-5D0F95E87B85Q61975170-5F6E9B0F-F5AB-4652-9D39-F060E5A3A240Q61975862-C70205DA-D453-426A-8754-47061AF89467Q62814009-A555DED4-8C6D-4F84-BB61-313DEE19718BQ63320167-6AB2EC89-CAD4-4A16-AAF3-4396B2310C1FQ63320179-499BF08D-EE53-4961-94F4-D93BFA963BB1Q63320187-B07FB607-2CCB-4737-AF1C-E525C50AC44BQ63320191-E9E2213C-3D53-4ADA-803F-25A616D5892DQ63320706-A70E9050-A6C6-427C-8AA5-AE0F94520F43Q63321004-308C805A-2D07-4F1B-A026-FD1925BD013AQ63334861-EB3D78E9-C48D-4E11-A046-99582D4A6F84Q63336345-D8AA80FC-E5BA-43C4-993A-F6CFBD85ACF6Q63338960-B13BC40B-0266-4969-958E-A8302AFDA0C7Q63338962-37CBC2EC-1493-41B0-8B87-EC6EED09B119Q63394634-08871FD1-F5BA-4AD3-A68F-9AF1862A7CE0Q63397220-0FE606EA-138A-41FF-86CB-92A1A3F430C8Q63402604-89413EB3-73AB-4166-9D29-445695FA37C2Q63572587-8D524895-D6FF-4F39-BAB1-57FC56E4A505Q63575163-FC11B2E6-B4EB-498A-926D-F03A3233AB54Q63598565-CF0D5139-DDE8-42C7-BED7-8E3ACB05A050Q87930693-F90C1E80-0DE4-4B2C-B96E-2DCF8A93892EQ89153686-6A85C335-BA92-4DF8-B9A8-8CDE97B608A6
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Mirabegron
@bar
Mirabegron
@de
Mirabegron
@fr
Mirabegron
@it
Mirabegron
@nl
Mirabegron
@sh
mirabegron
@en
mirabegron
@es
mirabegroni
@fi
mirabegró
@ca
type
label
Mirabegron
@bar
Mirabegron
@de
Mirabegron
@fr
Mirabegron
@it
Mirabegron
@nl
Mirabegron
@sh
mirabegron
@en
mirabegron
@es
mirabegroni
@fi
mirabegró
@ca
altLabel
Betmiga
@fi
Betmiga®
@de
Betmiga®
@en
Mirabegron
@en
Myrbetriq®
@de
Myrbetriq®
@en
YM-178
@de
YM-178
@en
myrbetriq
@es
prefLabel
Mirabegron
@bar
Mirabegron
@de
Mirabegron
@fr
Mirabegron
@it
Mirabegron
@nl
Mirabegron
@sh
mirabegron
@en
mirabegron
@es
mirabegroni
@fi
mirabegró
@ca